[Ezetimibe: caution in the face of doubt].
Araujo
F
F
Mateo de Castro
J
J
Encinas Barrios
C
C
D050197:Atherosclerosis / Q000209:etiology / Q000517:prevention & control; D001384:Azetidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D017292:Doxazosin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004363:Drug Utilization; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D009369:Neoplasms / Q000139:chemically induced*; D019821:Simvastatin / Q000008:administration & dosage / Q000627:therapeutic use; D014481:United States
D001384:Azetidines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D019821:Simvastatin; D000069438:Ezetimibe; D017292:Doxazosin